The receptors and tissues Ipamorelin reaches
Absorption brings the molecule into circulation. Receptor biology explains the next encounter, with a few complications beyond growth hormone.
What is Ipamorelin peptide?
Ipamorelin is a synthetic chain of five amino acids. It activates the ghrelin receptor, GHS-R1a, on growth hormone-releasing pituitary cells. A secretagogue is a substance that prompts secretion; in this case the signal prompts a growth hormone release.
The early work used rat pituitary cells, rats and swine. It found potent growth hormone release while ACTH and cortisol stayed near the levels seen with GHRH, even at amounts more than 200-fold above the growth hormone ED50. Prolactin also showed little change in the early characterization. I credit the molecule with that focused endocrine response.
What does Ipamorelin peptide do in cells?
The black seabream pituitary-cell experiment makes an unusually precise distinction. Ipamorelin stimulated hormone release without corresponding changes in growth hormone messenger RNA, including observations up to 48 hours. Messenger RNA carries the instructions for making a protein. In these fish cells, secretion and gene transcription behaved differently.
I admire the care with which secretion and transcription were distinguished. The culture dish contained pituitary cells from black seabream; its measurements concern those cells. Claims about a person's sleep or recovery would need another experiment altogether.
IGF-1, the pancreas and fat tissue
Growth hormone can stimulate the liver to produce IGF-1, a growth-related protein. Yet the short adult-female-rat bone study found faster longitudinal bone growth without a measurable increase in circulating IGF-1. The familiar hormone sequence therefore leaves room for different responses in different tissues.
There are further detours. Pancreatic tissue taken from normal and diabetic rats released insulin after exposure to Ipamorelin. That was an experiment outside the animals' bodies. Separately, growth hormone-deficient and growth hormone-intact mice both showed increased adiposity after Ipamorelin. Those additional tissue responses leave a plain growth hormone explanation looking incomplete to me. They remain preclinical findings, with the human metabolic response unresolved.
Ipamorelin vs sermorelin and tesamorelin
Sermorelin and tesamorelin mimic GHRH, the signal that normally comes from the brain. Ipamorelin activates the ghrelin receptor instead. The founding receptor and selectivity work explains the mechanistic distinction. It supplies no head-to-head demonstration that Ipamorelin improves a particular person's health more than either comparator.
For an Ipamorelin vs sermorelin or Ipamorelin vs tesamorelin question, I separate the known receptor difference from the missing clinical comparison. Choosing a winner would require a specified condition, population and outcome.
What is CJC 1295 Ipamorelin?
The name describes a proposed pairing of a GHRH analogue with a ghrelin-receptor agonist. Experiments with hexarelin and GHRH in healthy men and GHRP-6 during prolonged infusion provide class context for a larger hormone response when both signals are present. Those compounds and conditions need to stay attached to their findings.
The named CJC-1295 and Ipamorelin pair lacks a published human outcome trial. The human research and benefits pages address the clinical claims that people attach to this mechanism.